Science

Articles

• RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH
  15 November 2022, by Elodie DORMES

  Houston, TX, USA and Marseille, France, Nov. 15, 2022 (GLOBE NEWSWIRE) — RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the diagnostic of Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC). This radiotracer will serve as a companion diagnostic for future Targeted Alpha Therapy (TAT) for these cancers. 68Ga-RMX-VH is a (…)

• Vect-Horus and its academic partners describe the chemical optimisation of one of its lead peptides (Malcor et al., 2012, J Med Chem)
  28 January 2019, by Jonathan NOWAK

  and publish a review article on CNS drug delivery (Vlieghe and Khrestchatisky, 2012, Med Res Rev).

• 3rd Annual RNAi-Based Therapeutics Summit from April 19th to 21th, 2022, in Boston
  12 April 2022, by Elodie DORMES

  Michel KHRESTCHATISKY, Scientific Counsel, will have a talk entitled “Development of Molecular Vectors for Targeted Delivery of RNAi” and Elodie DORMES, Sr BD Manager, will also be there and pleased to meet you in person during the summit.

• Vect-Horus focuses on Target engagement and intracellular delivery of LDLR conjugates to design new targeted drug therapies
  27 November 2019, by Elodie DORMES

  Varini et al. J Control Release 2019
  Targeted delivery to specific tissues and subcellular compartments is of paramount importance to optimize therapeutic or diagnostic interventions while minimizing side-effects. Using recently identified LDL receptor (LDLR) -targeting small synthetic peptide-vectors conjugated to model cargos of different nature and size, we investigated in LDLR-expressing cells the impact of vector-cargo molecular engineering and coupling valency, as well as the (…)

• Séminaire M&M’s – Muscle Monday Seminars of the Institute’s Myology Centre for Research on January 17, 2022
  17 January 2022, by Elodie DORMES

  Michel Khrestchatisky (CNRS Research Director, Director of the Institute for Neurophysiopathology) Co-Founder & Scientific Counsel of Vect-Horus presents "Development of molecular vectors for targeted delivery of RNAi via receptor-mediated transport" at the Muscle Monday Seminars organized by the Institute’s Myology Centre for Research.